The 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (statins) are a class of drug used to lower low-density lipoprotein (LDL) levels. However, in recent years, statins have been shown to possess a pleiotropic effect beyond its cholesterol lowering ability, including attenuating the effect of ischaemia reperfusion injury. This review considers the biomolecular processes that may lead to this beneficial effect.
Keywords: Ischaemia reperfusion injury, statins, 3-hydroxy-3-methyl-glutaryl-CoA, reductase inhibitors, low-density lipoprotein, inflammatory re-sponse syndrome, multi organs dysfunction syn-drome, tissue hypoxia, hypoxanthine, xanthine oxidase, reactive oxygen species, nuclear factor B, activator protein-1, nitric oxide, endothelial dysfunction, inter-leukin (IL)-1, tumour necrosis factor alpha, platelet-activating factor, sialyl Lewis X, thrombin, cytokines, vascular endothelial cadherin, angioplasty, cholesterol biosynthesis, lovastatin, pravastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, rosuvastatin, cytochrome P450, coronary heart disease, rhabdo-myolysis, endothelial NO synthase, inducible NO synthase, neuronal NO synthase, Pro-Inflammatory Cytokines, PAF receptor, endothelin-1, monocyte chemoattractant protein-1, thrombomodulin, cytokine transcription, C-reactive protein, Leukocytes-Endothelial Interaction, decay-accelerating factor, protein kinase C, NADPH-oxidase, ROS reduction
Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury
Current Drug Targets Innate Immunity and the Heart
Current Pharmaceutical Design The Role of Prostaglandins in Liver Ischemia-Reperfusion Injury
Current Pharmaceutical Design Cerebral Hemorrhage Produced by Thrombolytic and Anti-Thrombotic Agents: A Review
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Myocardial Ischemia-Reperfusion Injury, Antioxidant Enzyme Systems, and Selenium: A Review
Current Medicinal Chemistry Mst1: Function and Mechanism in Brain and Myocardial Ischemia Reperfusion Injury
Current Neuropharmacology Oxidative Stress in Hepatic Ischemia-Reperfusion Injury: The Role of Antioxidants and Iron Chelating Compounds
Current Pharmaceutical Design The Application of Angiotensin Converting Enzyme Inhibitors in Heart Surgery
Letters in Drug Design & Discovery Manual Thrombectomy During Primary Coronary Intervention in Acute Myocardial Infarction: A Brief Review
Reviews on Recent Clinical Trials Mitochondria-Targeted Antioxidant Peptides
Current Pharmaceutical Design LncRNA MALAT1 is Neuroprotective in a Rat Model of Spinal Cord Ischemia-Reperfusion Injury Through miR-204 Regulation
Current Neurovascular Research Xanthine Derivatives in the Heart: Blessed or Cursed?
Current Medicinal Chemistry Protective Effects of Intermedin On Cardiovascular, Pulmonary and Renal Diseases: Comparison with Adrenomedullin and CGRP
Current Protein & Peptide Science Inhibition of sPLA2-IIA, C-reactive Protein or Complement: New Therapy for Patients with Acute Myocardial Infarction?
Cardiovascular & Hematological Disorders-Drug Targets Effect of Doxycycline on Atherosclerosis: From Bench to Bedside
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets Hsp20 Protects Neuroblastoma Cells from Ischemia/Reperfusion Injury by Inhibition of Apoptosis via a Mechanism that Involves the Mitochondrial Pathways
Current Neurovascular Research The Influence of Obese Insulin-Resistance on the Outcome of the Ischemia/Reperfusion Insult to the Heart
Current Medicinal Chemistry The Therapeutic Potential of Hepatocyte Growth Factor for Myocardial Infarction and Heart Failure
Current Pharmaceutical Design Resveratrol: A Therapeutic Promise for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery (Discontinued)